404!
申し訳ありませんが、
探していたページは存在しません。
ご指定されたページは「移動」「削除」又は「アドレスが間違っている」などの理由で表示することができません。
また、サイトリニューアルによりアドレスが変更された可能性があります。
サイト管理者へ連絡下さい。
Oncol LettersApr2020 Inhibition of miR‑18a‑3p reduces proliferation of mesothelioma cells and sensitizes them to cisplatin
Suzuki R, Amatya VJ, Kushitani K, Kai Y, Kambara T, Fujii Y, Takeshima Y.
Oncology Letters, 2020 Apr 1 read more
Suzuki R, Amatya VJ, Kushitani K, Kai Y, Kambara T, Fujii Y, Takeshima Y.
Oncology Letters, 2020 Apr 1 read more
HistopatholMar2019 Mucin 21 is a novel, negative immunohistochemical marker for epithelioid mesothelioma for its differentiation from lung adenocarcinoma.
Kai Y, Amatya VJ, Kushitani K, Kambara T, Suzuki R, Tsutani Y, Miyata Y, Okada M, Takeshima Y.
Histopathology. 2019 Mar;74(4):545-554. read more
Kai Y, Amatya VJ, Kushitani K, Kambara T, Suzuki R, Tsutani Y, Miyata Y, Okada M, Takeshima Y.
Histopathology. 2019 Mar;74(4):545-554. read more
Mod PatholJan2019 Reply to 'MUC4 staining in sarcomatoid carcinomas' by Berg et al.
Amatya VJ, Kushitani K, Mawas AS, Miyata Y, Okada M, Kishimoto T, Inai K, Takeshima Y.
Mod Pathol 32:158, 2019. read more
Amatya VJ, Kushitani K, Mawas AS, Miyata Y, Okada M, Kishimoto T, Inai K, Takeshima Y.
Mod Pathol 32:158, 2019. read more
Front OncolDec2018 miR-182 and miR-183 Promote Cell Proliferation and Invasion by Targeting FOXO1 in Mesothelioma.
Suzuki R, Amatya VJ, Kushitani K, Kai Y, Kambara T, Takeshima Y.
Front Oncol 8:446, 2018 read more
Suzuki R, Amatya VJ, Kushitani K, Kai Y, Kambara T, Takeshima Y.
Front Oncol 8:446, 2018 read more
Mod PatholJan2018
Glypican-1 immunohistochemistry is a novel marker to differentiate epithelioid mesothelioma from lung adenocarcinoma
Amatya VJ, Kushitani K, Kai Y, Suzuki R, Miyata Y, Okada M, Takeshima Y.
Mod Pathol 31(5):809-815, 2018 read more
Amatya VJ, Kushitani K, Kai Y, Suzuki R, Miyata Y, Okada M, Takeshima Y.
Mod Pathol 31(5):809-815, 2018 read more
Oncol LettJan2018
Utility of Survivin, BAP1, and Ki‑67 immunohistochemistry in distinguishing epithelioid mesothelioma from reactive mesothelial hyperplasia
Kushitani K, Amatya VJ, Mawas AS, Suzuki R, Miyata Y, Okada M, Inai K, Kishimoto T, Takeshima Y.
Oncol Lett 15(3):3540-3547, 2018 read more
Kushitani K, Amatya VJ, Mawas AS, Suzuki R, Miyata Y, Okada M, Inai K, Kishimoto T, Takeshima Y.
Oncol Lett 15(3):3540-3547, 2018 read more
Sci RepJan2018
MUC4 immunohistochemistry is useful in distinguishing epithelioid mesothelioma from adenocarcinoma and squamous cell carcinoma of the lung.
Mawas AS, Amatya VJ, Kushitani K, Kai Y, Miyata Y, Okada M, Takeshima Y.
Sci Rep 8(1):134. read more
Mawas AS, Amatya VJ, Kushitani K, Kai Y, Miyata Y, Okada M, Takeshima Y.
Sci Rep 8(1):134. read more
Am J Surg PatholAug2017
Identification of DAB2 and Intelectin-1 as Novel Positive Immunohistochemical Markers of Epithelioid Mesothelioma by Transcriptome Microarray Analysis for its Differentiation From Pulmonary Adenocarcinoma.
Kuraoka M, Amatya VJ, Kushitani K, Mawas AS, Miyata Y, Okada M, Kishimoto T, Inai K, Nishisaka T, Sueda T, Takeshima Y.
Am J Surg Pathol. 2017; 41(8):1045-1052 read more
Kuraoka M, Amatya VJ, Kushitani K, Mawas AS, Miyata Y, Okada M, Kishimoto T, Inai K, Nishisaka T, Sueda T, Takeshima Y.
Am J Surg Pathol. 2017; 41(8):1045-1052 read more
Mod PatholMay2017
MUC4, a novel immunohistochemical marker identified by gene expression profiling, differentiates pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma.
Amatya VJ, Kushitani K, Mawas AS, Miyata Y, Kishimoto T, Okada M, Inai K, Takeshima Y.
Mod Pathol. 2017; 30(5): 672-681 read more
Amatya VJ, Kushitani K, Mawas AS, Miyata Y, Kishimoto T, Okada M, Inai K, Takeshima Y.
Mod Pathol. 2017; 30(5): 672-681 read more
Int J oncolMar2017 PIM1 knockdown inhibits cell proliferation and invasion of mesothelioma cells.
Mawas AS, Amatya VJ, Suzuki R, Kushitani K, Mohi El-Din MM, Takeshima Y.
Int J Oncol; 2017 Mar; 50(3):1029-1034 read more
Mawas AS, Amatya VJ, Suzuki R, Kushitani K, Mohi El-Din MM, Takeshima Y.
Int J Oncol; 2017 Mar; 50(3):1029-1034 read more
HistopatholFeb2017 Utility and pitfall of Immunohistochemistry in the Differential Diagnosis between Epithelioid Mesothelioma and Poorly Differentiated Lung Squamous Cell Carcinoma.
Kushitani K, Amatya VJ, Okada Y, Katayama Y, Mawas AS, Miyata Y, Okada M, Inai K, Kishimoto T, Takeshima Y.
Histopathology. 2017; 70(3): 375-384 read more
Kushitani K, Amatya VJ, Okada Y, Katayama Y, Mawas AS, Miyata Y, Okada M, Inai K, Kishimoto T, Takeshima Y.
Histopathology. 2017; 70(3): 375-384 read more
HistopatholFeb2017 Utility and pitfall of Immunohistochemistry in the Differential Diagnosis between Epithelioid Mesothelioma and Poorly Differentiated Lung Squamous Cell Carcinoma.
Kushitani K, Amatya VJ, Okada Y, Katayama Y, Mawas AS, Miyata Y, Okada M, Inai K, Kishimoto T, Takeshima Y.
Histopathology. 2017; 70(3): 375-384 read more
Kushitani K, Amatya VJ, Okada Y, Katayama Y, Mawas AS, Miyata Y, Okada M, Inai K, Kishimoto T, Takeshima Y.
Histopathology. 2017; 70(3): 375-384 read more
